Ajanta Choudhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ajanta Choudhury has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Mayank Choubey
New York University Grossman Long Island School of Medicine
2 shared publications - Mohammad Mohabbulla Mohib
Department of Pharmaceutical Sciences, North South University, Dhaka 1229, Bangladesh
2 shared publications - Mohammad Sarif Mohiuddin
Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, 101 Mineola Blvd, Mineola, NY 11501, USA
2 shared publications - Naofel Minhaz
PGY1, Family Medicine, University of Alberta, 116 St & 85 Ave, Edmonton, AB T6G 2R3, Canada
2 shared publications - Pallab Sarker
Department of Internal Medicine, Sher-e-Bangla Medical College Hospital, Band Rd., Barishal 8200, Bangladesh
2 shared publications - Rashu Barua
Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY, United States
2 shared publications
Latest Publications
- Open Access
- 18 August 2023
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 5 (3) , 340-355
The Effect of COVID-19 on Gut Microbiota: Exploring the Complex Interplay and Implications for Human Health
The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to significant global health implications. Although the respiratory manifestations of COVID-19 are widely recognized, emerging evidence suggests that the disease may also significantly affect the gut microbiota, the intricate community of bacteria that lives within the gastrointestinal system. This extensive article intends to investigate the impact of COVID-19 on the gut microbiota, examining the underlying mechanisms, clinical implications, and potential therapeutic interventions. Understanding the complex interactions between COVID-19 and the gut microbiota will help us to gain valuable insights into the broader consequences of this viral infection on human health.
- 18 August 2023
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 5 (3) , 340-355
Open AccessThe Effect of COVID-19 on Gut Microbiota: Exploring the Complex Interplay and Implications for Human Health
The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to significant global health implications. Although the respiratory manifestations of COVID-19 are widely recognized, emerging evidence suggests that the disease may also significantly affect the gut microbiota, the intricate community of bacteria that lives within the gastrointestinal system. This extensive article intends to investigate the impact of COVID-19 on the gut microbiota, examining the underlying mechanisms, clinical implications, and potential therapeutic interventions. Understanding the complex interactions between COVID-19 and the gut microbiota will help us to gain valuable insights into the broader consequences of this viral infection on human health.
- Open Access
- 19 July 2023
- Published by MDPI AG in Preprints.org
The Effect of COVID-19 on Gut Microbiota: Exploring the Complex Interplay and Implications for Human Health
The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to significant global health implications. Although the respiratory manifestations of COVID-19 are widely recognized, emerging evidence suggests that the disease may also significantly affect the gut microbiota, the intricate community of bacteria that lives within the gastrointestinal system. This extensive article intends to investigate the impact of COVID-19 on the gut microbiota, examining the underlying mechanisms, clinical implications, and potential therapeutic interventions. Understanding the complex interactions between COVID-19 and the gut microbiota will help us to gain valuable insights into the broader consequences of this viral infection on human health.
- 19 July 2023
- Published by MDPI AG in Preprints.org
Open AccessThe Effect of COVID-19 on Gut Microbiota: Exploring the Complex Interplay and Implications for Human Health
The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to significant global health implications. Although the respiratory manifestations of COVID-19 are widely recognized, emerging evidence suggests that the disease may also significantly affect the gut microbiota, the intricate community of bacteria that lives within the gastrointestinal system. This extensive article intends to investigate the impact of COVID-19 on the gut microbiota, examining the underlying mechanisms, clinical implications, and potential therapeutic interventions. Understanding the complex interactions between COVID-19 and the gut microbiota will help us to gain valuable insights into the broader consequences of this viral infection on human health.
- Open Access
- 29 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39653
A Rare Case of Acute Cholecystitis Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in an Immunocompetent Person in the Absence of Bacteremia or Pre-Existing Conditions
Acute cholecystitis, typically caused by gallstone obstruction of the cystic duct, is often complicated by infection. Mostly observed in immunocompromised patients with bacteremia Methicillin-resistant Staphylococcus aureus (MRSA) is not typically associated with this ailment. Here, we present a unique case of acute cholecystitis caused by MRSA in an immunocompetent patient without bacteremia or underlying disease. A male patient aged 59 years was admitted complaining of severe abdominal pain and nausea. Subsequent investigation confirmed acute calculous cholecystitis and thereafter, the patient underwent laparoscopic cholecystectomy. Gallbladder fluid culture indicated elevated quantities of MRSA growths, and suitable antimicrobial therapy was given as part of the treatment process. This exceptional case underlines the significance of recognizing MRSA as a potential pathogen in severe acute cholecystitis cases, particularly those with severe symptoms. Rapid identification and usage of anti-MRSA antibiotics play a crucial role in managing MRSA-related situations. Healthcare providers need to bear in mind the possibility of cholecystitis associated with MRSA particularly when conventional risk factors are not present. Timely intervention is essential for favorable patient outcomes.
- 29 May 2023
- Published by Springer Nature in Cureus
- Vol. 15 (5) , e39653
Open AccessA Rare Case of Acute Cholecystitis Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in an Immunocompetent Person in the Absence of Bacteremia or Pre-Existing Conditions
Acute cholecystitis, typically caused by gallstone obstruction of the cystic duct, is often complicated by infection. Mostly observed in immunocompromised patients with bacteremia Methicillin-resistant Staphylococcus aureus (MRSA) is not typically associated with this ailment. Here, we present a unique case of acute cholecystitis caused by MRSA in an immunocompetent patient without bacteremia or underlying disease. A male patient aged 59 years was admitted complaining of severe abdominal pain and nausea. Subsequent investigation confirmed acute calculous cholecystitis and thereafter, the patient underwent laparoscopic cholecystectomy. Gallbladder fluid culture indicated elevated quantities of MRSA growths, and suitable antimicrobial therapy was given as part of the treatment process. This exceptional case underlines the significance of recognizing MRSA as a potential pathogen in severe acute cholecystitis cases, particularly those with severe symptoms. Rapid identification and usage of anti-MRSA antibiotics play a crucial role in managing MRSA-related situations. Healthcare providers need to bear in mind the possibility of cholecystitis associated with MRSA particularly when conventional risk factors are not present. Timely intervention is essential for favorable patient outcomes.